Matisyahu Shulman1, Sean X Luo, Aimee N C Campbell, Jennifer Scodes, Martina Pavlicova, Andi Broffman, Andrew J Saxon, Edward V Nunes. 1. New York State Psychiatric Institute, New York, NY, (MS, SL, ANCC, JS, AB, EVN); Department of Psychiatry, Columbia University Medical Center, New York, NY, (MS, SL, ANCC, JS, EVN); Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY, (MP); Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine; Center of Excellence in Substance Abuse Treatment and Education VA Puget Sound Health Care System, WA (AJS).
Abstract
OBJECTIVE: Opioid use disorder (OUD) is associated with chronic pain. We investigated the association between medication treatments for OUD and pain in a post-hoc secondary analysis of a randomized trial of methadone versus buprenorphine/naloxone. METHODS: 1241 individuals with OUD participated in an open label, pragmatic randomized trial of methadone versus buprenorphine/naloxone in nine treatment programs licensed to dispense agonist medication for OUD between 2006 to 2009. In this post-hoc analysis, pain was dichotomized (present or not present) using responses from the Short Form-36. Logistic regression models were fit to test the effect of (1) having baseline pain on week 24 retention, (2) treatment assignment on improvement in pain among those reporting pain at baseline, and (3) pain improvement at week 4 on week 24 retention among those reporting pain at baseline. RESULTS: Almost half (48.2%) of the sample reported pain at baseline. Participants with baseline pain did not significantly differ in week 24 retention compared to those without baseline pain. Among those reporting pain at baseline, there was no significant difference between treatment arms in improvement of pain at week 4, but improvement in pain at week 4 was associated with significantly greater odds of being retained at week 24 (OR [95% CI] = 1.76 [1.10, 2.82], P = 0.020). CONCLUSION AND RELEVANCE: In this large multisite randomized trial of medication treatments for OUD, nearly half of the participants reported pain at baseline, and improvement in pain early in treatment was associated with increased likelihood of retention in treatment.
OBJECTIVE: Opioid use disorder (OUD) is associated with chronic pain. We investigated the association between medication treatments for OUD and pain in a post-hoc secondary analysis of a randomized trial of methadone versus buprenorphine/naloxone. METHODS: 1241 individuals with OUD participated in an open label, pragmatic randomized trial of methadone versus buprenorphine/naloxone in nine treatment programs licensed to dispense agonist medication for OUD between 2006 to 2009. In this post-hoc analysis, pain was dichotomized (present or not present) using responses from the Short Form-36. Logistic regression models were fit to test the effect of (1) having baseline pain on week 24 retention, (2) treatment assignment on improvement in pain among those reporting pain at baseline, and (3) pain improvement at week 4 on week 24 retention among those reporting pain at baseline. RESULTS: Almost half (48.2%) of the sample reported pain at baseline. Participants with baseline pain did not significantly differ in week 24 retention compared to those without baseline pain. Among those reporting pain at baseline, there was no significant difference between treatment arms in improvement of pain at week 4, but improvement in pain at week 4 was associated with significantly greater odds of being retained at week 24 (OR [95% CI] = 1.76 [1.10, 2.82], P = 0.020). CONCLUSION AND RELEVANCE: In this large multisite randomized trial of medication treatments for OUD, nearly half of the participants reported pain at baseline, and improvement in pain early in treatment was associated with increased likelihood of retention in treatment.
Authors: Roger D Weiss; Jennifer Sharpe Potter; David A Fiellin; Marilyn Byrne; Hilary S Connery; William Dickinson; John Gardin; Margaret L Griffin; Marc N Gourevitch; Deborah L Haller; Albert L Hasson; Zhen Huang; Petra Jacobs; Andrzej S Kosinski; Robert Lindblad; Elinore F McCance-Katz; Scott E Provost; Jeffrey Selzer; Eugene C Somoza; Susan C Sonne; Walter Ling Journal: Arch Gen Psychiatry Date: 2011-11-07
Authors: R Douglas Bruce; Jessica Merlin; Paula J Lum; Ebtesam Ahmed; Carla Alexander; Amanda H Corbett; Kathleen Foley; Kate Leonard; Glenn Jordan Treisman; Peter Selwyn Journal: Clin Infect Dis Date: 2017-10-30 Impact factor: 9.079
Authors: Jennifer Sharpe Potter; Amit Chakrabarti; Catherine P Domier; Maureen P Hillhouse; Roger D Weiss; Walter Ling Journal: J Subst Abuse Treat Date: 2010-06
Authors: Declan T Barry; Mark Beitel; Brian Garnet; Dipa Joshi; Andrew Rosenblum; Richard S Schottenfeld Journal: J Clin Psychiatry Date: 2009-07-14 Impact factor: 4.384
Authors: Eric L Garland; Eron G Manusov; Brett Froeliger; Amber Kelly; Jaclyn M Williams; Matthew O Howard Journal: J Consult Clin Psychol Date: 2014-02-03
Authors: Mary Jo Larson; Michael Paasche-Orlow; Debbie M Cheng; Christine Lloyd-Travaglini; Richard Saitz; Jeffrey H Samet Journal: Addiction Date: 2007-05 Impact factor: 6.526
Authors: Honoria Guarino; Chunki Fong; Lisa A Marsch; Michelle C Acosta; Cassandra Syckes; Sarah K Moore; Ricardo A Cruciani; Russell K Portenoy; Dennis C Turk; Andrew Rosenblum Journal: Pain Med Date: 2018-12-01 Impact factor: 3.750